Proxy contests and exempt solicitations in last 3 years
No recent proxy contest or exempt solicitation filings from shareholders.
Vote support at last AGM
On September 24, 2020, Axovant Gene Therapies Ltd. (the “Company”) held its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders considered and approved two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 12, 2020.
Of the 41,797,294 common shares outstanding as of the record date, 37,014,259 shares, or 88.6%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.
Proposal No. 1: The following six nominees for director were elected to serve as directors of the Company until the Company’s 2021 Annual General Meeting of Shareholders and until their successors are duly elected, by the following votes:
Frank Torti, M.D.
Atul Pande, M.D.
Pavan Cheruvu, M.D.
Eric Venker, M.D., Pharm.D.
Proposal No. 2: The shareholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending March 31, 2021 and the appointment of Ernst & Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for its fiscal year ending March 31, 2021, and authorized the Company’s Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company’s auditor for its fiscal year ending March 31, 2021, by the following votes: